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ABSTRACT 
 
     A high incidence of bone disease in patients with inflammatory bowel 
disease (IBD) requires frequent monitoring of skeletal status, and for that 
reason evaluation of radiation free technology is an issue of interest. Our 
objective was to appraise the parameters of calcaneal quantitative ultrasound 
(QUS): broadband ultrasound attenuation (BUA), speed of sound (SOS) and 
stiffness index (QUI), and establish their t-score values to investigate 
discriminatory ability of QUS in IBD patients with metabolic bone disease. 
     The study included 126 patients (Crohn's disease n=94, and ulcerative 
colitis n=32), and 228 age- and sex-matched healthy volunteers. Bone status 
was evaluated on the same day by calcaneal QUS and dual-energy x-ray 
absorptiometry (DXA) at spine (L1-L4) and total hip. 
     All QUS measurements were lower in patients compared with healthy 
controls (BUA p<0.001; SOS p<0.001; QUI p<0.001) and correlated 
significantly but inversely with disease duration (r=-0.3, p=0.002). There was 
no difference with respect to type of disease (Crohn's disease or ulcerative 
colitis) or corticosteroid therapy. All three QUS t-scores were significantly 
lower in patients who had previously sustained fragile fractures (n=28) than in 
those without fracture in their history (n=98) (t-scores: BUA -2.0 vs. -1.3, 
p=0.008; SOS -2.1 vs. -1.4, p=0.02: QUI -2.3 vs. -1.5, p=0.009). Axial DXA 
was not significantly different between the fracture and non-fracture patients (-
1.7 vs. -1.2, p=0.1), whereas total hip DXA showed a discriminatory power 
between the two (-1.6 vs. -0.7, p=0.001).  Patients with t-score <-1.0 scanned 
by DXA were classified as bone disease. The sensitivity of QUS to identify 
bone disease was 93% and specificity 63%. The sensitivity of QUS to detect 
osteopenia was 84% and 72% for osteoporosis. Alternatively, less negative 
QUS t-score cut-off ≤ -1.8 identified 83% of osteoporosis at lumbar spine and 
100% at total hip. All three QUS variables had t-scores less than -1.8 when 
osteoporosis was detected at both spine and hip.  However, the subgroup of 
IBD patients with QUI t-score cut-off ≤-1.8 still included 26% of individuals 
with normal bone status. 
     Calcaneal QUS measurements may identify patients with inflammatory 
bowel disease at a higher risk of fracture, independently of DXA 
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measurements. However, QUS showed poor agreement with bone status 
scanned by DXA and a low discriminatory power between osteopenia and 
osteoporosis. 
 
KEY WORDS 
Inflammatory bowel disease; Metabolic bone disease; Calcaneal quantitative 
ultrasound; Dual-energy x-ray absorptiometry; Specificity; Sensitivity 
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INTRODUCTION 
 
Metabolic bone disease is an established complication in patients with 
inflammatory bowel disease (IBD) (Bernstein et al. 2003; Harpavat et al. 2004; 
Kirchgatterer et al. 2002; Lichtenstein 2003; Schoon et al. 2000; Schulte 
2004). Bone lesions ranging from variable osteopenia to osteoporosis with a 
consequential increased risk of bone fractures have been described in both 
Crohn's disease and ulcerative colitis (Schoon et al. 2000). The etiology of 
bone changes in IBD is rather complex. It is known that skeletal system may 
be affected by chronic remittent inflammation per se and corticosteroid 
medications used in the treatment of disease, or by genetic susceptibility to 
bone loss (Schulte 2004). Bone mineral density (BMD) at the femoral neck 
and lumbar spine is a critical parameter to measure bone mass and fracture 
risk. Dual-energy x-ray absorptiometry (DXA) is the current gold standard 
technique for measuring BMD. Studies using DXA, published to date, report 
that 40%-50% of patients with IBD have osteopenia and as many as 30% of 
individuals have osteoporosis (Kirchgatterer et al. 2002; Lichtenstein 2003). 
Generally, osteopenia and osteoporosis are more frequently seen in patients 
with Crohn's disease than in patients with ulcerative colitis (Lichtenstein 
2003). 
Quantitative ultrasound (QUS) is an alternative technology for monitoring 
skeletal status. It is a non-invasive technique that may be useful in assessing 
bone structure as well as bone mass. QUS has the advantages of being 
radiation-free and using relatively inexpensive, portable devices. The two 
ultrasound variables currently measured are broadband ultrasound 
attenuation (BUA) and speed of sound (SOS). In vitro studies of cancellous 
bone specimens have demonstrated BUA to be associated with trabecular 
bone structure, while SOS parameters depend more on elasticity and density 
(Bouxsein and Radloff 1997). QUS technology is suitable for recurrent 
measurements and monitoring of bone status at peripheral sites, such as the 
calcaneus, phalanges and tibia (Cook et al. 2005). QUS technique has been 
shown to be a good predictor of fracture risk in postmenopausal women, 
independent of DXA (Knapp et al 2001). Calcaneal QUS has also been 
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demonstrated to discriminate low bone density in patients with rheumatoid 
arthritis and to detect bone changes in corticosteroid users (Maricic 2004).  
Only a few previous studies referred QUS data in IBD patients, with 
controversial results. QUS was found to be useful as a screening tool for 
metabolic bone disease in four studies (Fries et al. 1998; Hartman et al. 2004; 
Javaid et al. 2001; Zadik et al. 2005) but not in another five (Jahnsen et al. 
1999; Levine et al. 2002; Robinson et al. 1998; Schwartz et al. 2005; von 
Tirpitz et al. 2003). As in IBD patients bone pathology is developing since 
young age and may progress over a shorter period of time than in 
postmenopausal osteoporosis, monitoring of bone status by DXA should be 
performed frequently. That is why the evaluation of an alternative, radiation 
frees technology, remains an issue of interest. Therefore, the aim of the 
present study was first to establish t-score values for individual QUS 
parameters; BUA, SOS and QUI-stiffness index were converted into t-scores 
to reflect the number of standard deviations below the mean of reference 
values in the control population. Namely, all reports referring to QUS data in 
IBD patients provided and analyzed solely crude values for QUS variables. In 
the present study, bone status was first classified by use of QUS t-scores, and 
then we investigated whether the data obtained by QUS could serve as an 
alternative or complementary option to those established by DXA.  
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SUBJECTS and METHODS 
 
Subjects and study design 
 A total of 126 patients with inflammatory bowel disease (Crohn's disease 
n=94, and ulcerative colitis n=32) diagnosed according to conventional 
clinical, radiological, endoscopic, and histological criteria were recruited. 
Baseline characteristics of patients are shown in Table 1. Clinical data were 
collected from hospital records. None of the patients had a history of 
treatment with any medication affecting bone density other than 
corticosteroids, prior to the study. Moreover, the patients were not treated with 
vitamin D and calcium supplements. Data on corticosteroid use were 
categorized into two groups: never used, and corticosteroid therapy (≥ 8 mg 
prednison/day) over 3 months. Duration of disease and body mass index 
(BMI) were calculated. Twenty-eight patients (9 with osteoporosis and 19 with 
osteopenia) reported a history of fragile fractures. In order to obtain a control 
group of healthy individuals age- and sex-matched to the study group of IBD 
patients, we selected 228 healthy volunteers (median age 33.5, range 21-45 
years) receiving no medication nor suffering from conditions affecting bone 
density or from any known disease. The local reference population was 
recruited from general practitioners, hospital personnel and their friends. The 
investigation was designed and carried out in accordance with the principles 
of the Declaration of Helsinki as revised in 2000. The Hospital Ethics 
Committee approved the study protocol, and informed written consent was 
obtained from each subject before entering the study. 
 
Bone status measurements 
Bone mineral density (BMD) of lumbar spine (L1-L4) and total hip (femoral 
neck and trochanter) was measured by the absorptiometric technique (DXA) 
using a Delphi W (S/N 700483) instrument (Hologic, Inc., Waltham, MA, 
USA). BMD measurements were converted into t-scores reflecting the number 
of standard deviations below the mean for a young healthy population, and z-
scores reflecting the number of standard deviations below the mean for age-
matched controls (database gathered by Hologic). According to the WHO 
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guidelines, osteopenia was defined as a t-score between -1 and -2.5, and 
osteoporosis as a t-score less than -2.5. 
Calcaneal structure was measured in all subjects on the left heel using 
the Sahara bone sonometer (Hologic, Inc., Waltham, MA, USA). The 
measurements included broadband ultrasound attenuation (BUA), speed of 
sound (SOS), BMD with t-score, and stiffness index (QUI). BUA (dB/MHz) is a 
parameter that describes the energy loss of an ultrasound wave as it passes 
through the os calcis. SOS denotes the speed of sound expressed in m/s, 
which is the passing distance of a sound wave divided by transit time. QUI is 
a mathematical index and provides a linear combination of BUA and SOS. 
The Hologic manufacturer's reference data for Sahara QUS parameters BUA, 
SOS and QUI, and related t-scores were not available. Therefore, 
reference values for BUA, SOS, QUI (mean±SD), and related individual t-
scores were calculated from our own reference group of healthy volunteers, 
using the formula: T-score = (individual measurement – mean of 
reference)/SD of reference (Cook et al. 2005). The in vivo precision of BUA 
and SOS were estimated by repeat measurements on the left heel with 
repositioning. Coefficients of variation in 30 healthy subjects were 2.7% for 
BUA and 0.4% for SOS, which is consistent with literature data. However, 
precision was poorer in the high-risk group of 30 IBD patients; coefficient of 
variation was 17.3% for repeat BUA measurement and 0.9% for SOS. All 
measurements were done on the same day, in identical conditions, and by the 
same operator. 
 
Statistical analysis 
Analysis of data was performed using the StatSoft statistical package. 
Results for continuous variables are given as mean±SD or range, and for non-
continuous variables as frequency and percentage. Comparison for 
differences among variables was tested by ANOVA and nonparametric Mann 
Whitney U-test, Kruskal-Wallis ANOVA or Wilcoxon matched pair test when 
appropriate. Bivariate correlation was examined by Spearman, and multiple 
stepwise regression analysis was used for association among variables. 
Patients with t-score <-1.0 scanned by DXA were classified as “bone disease” 
and those with DXA t-score >-1.0 as “normal”. Results obtained by QUS 
   
 8 
technique relative to DXA diagnosis were expressed by 2*2 contingency table 
and their validity assessment was calculated. Precision was assessed by 
determination of coefficient of variation. 
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RESULTS 
 
Calcaneal QUS measurements 
Crude values of the QUS parameters of BUA, SOS and QUI for all study 
patients and reference population are shown in Table 2. Reference values for 
BUA t-scores, SOS t-scores and QUI t-scores were calculated from the local 
reference population of 228 healthy volunteers that were age-and sex-
matched to the study group of IBD patients. All three calcaneal t-scores were 
significantly lower in patients compared with healthy volunteers (BUA 
p<0.001; SOS p<0.001; QUI p<0.001). ANOVA analysis of calcaneal QUS 
variables showed no significant differences between patients with Crohn's 
disease (n=94) and ulcerative colitis (n=32) (BUA p=0.27; SOS p=0.82; QUI 
p=0.62). There were no differences in t-scores measured by DXA at lumbar 
spine (p=0.68) and total hip (p=0.061) between the the two groups of IBD 
patients. Additionally, corticosteroid treatment lasting for more than 3 months 
in lifetime was analyzed as a categorized variable. QUS t-scores were lower 
in corticosteroid users (n=77) than in patients free from corticosteroid therapy 
(n=49), however, the difference did not reach statistical significance (t-scores: 
BUA -1.6 vs. -1.3, p=0.24; SOS -1.7 vs. -1.4, p=0.14; QUI -1.8 vs. -1.5, 
p=0.19). Corticosteroid therapy was associated with lower DXA t-scores in 
corticosteroid users, however, without statistical significance (spine: -1.02 vs -
1.49, p=0.101; total hip: -0.74 vs -1.04, p=0.16). When age, disease duration 
and body mass index were taken into account, stepwise multiple regression 
analysis indicated that disease duration significantly predicted QUS variables 
(p<0.01). All study parameters of calcaneal QUS showed a significant inverse 
correlation with disease duration (r=-0.3, p=0.002) (Fig. 1). Twenty-three 
percent of IBD patients reported previous fractures in their history. All three 
calcaneal t-scores were significantly lower in patients who had previously 
sustained fragile fractures (n=28) than in those without fracture in their history 
(n=98) (t-scores: BUA -2.0 vs. -1.3, p=0.008; SOS -2.1 vs. -1.4, p=0.02: QUI -
2.3 vs. -1.5, p=0.009) (Fig. 2). Axial DXA was not significantly different 
between the fracture and non-fracture patients (-1.7 vs. -1.2, p=0.1), whereas 
total hip DXA showed a discriminatory power between the two (-1.6 vs. -0.7, 
p=0.001). 
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DXA versus QUS measurements 
According to the WHO guidelines (WHO Study Group Report 1994) based 
on the results produced by DXA at lumbar spine and total hip, study patients 
(n=92) were divided into three subgroups: normal bone status (n=38; 41%), 
osteopenia (n=36; 39%) and osteoporosis (n=18; 20%) detected at least at 
one measurement site. In these patients, t-scores for calcaneal QUS-stiffness 
index (a combination of BUA and SOS) identified 28 (30%) subjects with 
normal bone status, whereas bone changes were detected as osteopenia in 
45 (49%) and as osteoporosis in 19 (21%) patients. Osteoporosis scanned by 
DXA was confirmed by QUS parameters in 13/18 cases, and detected as 
osteopenia in 5/18 cases. However, none of the osteoporosis cases scanned 
by DXA was falsely detected by calcaneal QUS as normal bone status. Yet, 
the analysis of sensitivity and specificity as measures of test validity revealed 
a greater discrepancy. All patients with t-score <-1.0 scanned by DXA were 
classified as bone disease. The sensitivity of QUS-index to identify bone 
disease was 93% and specificity 63%. The calculated positive predictive value 
of QUS was 78%, and negative predictive value 86%. The sensitivity of QUS 
to detect osteopenia properly was 84% and for osteoporosis only 72%. Kappa 
statistica showed moderate agreement between QUS and DXA (κ=0,58 
SE(κ)=0,15 z=3,9) 
In another attempt to use QUS measurements for assessment of skeletal 
status in IBD patients, a less negative QUS t-score cut-off ≤ -1.8 was chosen, 
as suggested by Frost et al. (2000). Thus, QUI t-score ≤ -1.8 identified 83% of 
cases with osteoporosis, 56% with osteopenia and 26% with normal bone 
status scanned by DXA. As DXA results for osteoporosis compared between 
different skeletal sites vary, we analyzed agreement between QUI and DXA at 
L1-L4 spine and separately between QUI and total hip. QUI t-score ≤ -1.8 
identified 100% of hip osteoporosis and 83% of lumbar spine osteoporosis. 
When osteoporosis was detected by DXA at both spine and hip, all three QUS 
variables had t-scores less than -1.8: BUA -3.0 (range -4.3 to -2.2), SOS -2.6 
(range -3.2 to -1.85) and QUI -3.0 (range -3.7 to -2.2). 
 
   
 11 
DISCUSSION 
 
In recent years, a high incidence of metabolic bone disease in patients 
with inflammatory bowel disease has been recognized as a problem and 
preventive screening has been recommended (Papaionnou et al. 2001; 
Valentine and Sninsky 1999). The present study investigated the general 
ability of calcaneal QUS parameters to discriminate IBD patients according to 
bone status. The study population of IBD patients included 41% of patients 
with normal bone status, 39% of patients with osteopenia and 20% of patients 
with osteoporosis. The criterion for establishing metabolic bone disease was 
the finding of BMD produced by lumbar spine and/or total hip DXA. In order to 
make QUS data comparable with the parameters of classical densitometry, 
each individual QUS parameter was converted into t-score. Normative values 
for BUA t-scores, SOS t-scores and QUI t-scores were calculated from our 
own reference group of 228 healthy volunteers. 
There were several strengths of calcaneal QUS measurements. First, all 
QUS t-scores (BUA, SOS and QUI) discriminated IBD patients from healthy 
age- and sex-matched controls. Second, there were significant differences in 
the mean values of calcaneal QUS between fracture and non-fracture 
patients. Third, none of osteoporosis cases was falsely detected by calcaneal 
QUS as normal bone status. Finally, all QUS parameters showed a significant 
inverse correlation with disease duration. Despite all these facts, the 
sensitivity (93%), specificity (63%) and positive predictive value (78%) of 
calcaneal QUS measurements failed to support QUS as a valuable method in 
discriminating IBD patients with bone disease. Our observations are 
comparable to some previously published studies evaluating clinical value of 
calcaneal QUS measurements in IBD patients. Schwartz et al (2005) 
compared QUS and DXA in 124 IBD patients, 62% of them with DXA t-score 
≤-1.0, and found that calcaneal QUS sensitivity and specificity were too low to 
be clinically useful. In a study reported by Jansen et al (1999) the correlation 
between calcaneal QUS and DXA measurements ranged from 0.50 to 0.67, 
yet the agreement between measurements in individual patients was poor. In 
our study, the 93% sensitivity implied 7% of patients with established bone 
disease to be classified as false negative, whereas 63% specificity indicated 
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as many as 37% of subjects with normal bone status to be classified as false 
positive. We should point out that the patients classified as false positive had 
calcaneal QUS parameters indicative of variable osteopenia. The fact that 
QUS failed to differentiate osteoporosis from osteopenia (in 28% of cases) 
appears to be of major clinical relevance, as this differentiation is a condicio 
sine qua non for the introduction of treatment with highly potent antiresorptive 
agents. Frost et al (2000) consider that WHO criteria (t-score ≤-2.5) for 
diagnosing osteoporosis in postmenopausal women cannot be applied to 
calcaneal QUS. The QUS parameters BUA and SOS do not measure bone 
mineral content, whereas WHO classification is based on bone mineral 
density. Therefore, these authors suggest a less negative t-score threshold of 
-1.8 for QUS as a tool to compare QUS and DXA. This approach was 
alternatively used in our study, and QUI t-score cut-off ≤-1.8 identified 83% of 
osteoporosis at lumbar spine and 100% at total hip. All three QUS variables 
had t-scores less than -1.8 when osteoporosis was detected at both spine and 
hip. However, the subgroup of IBD patients with QUI t-score cut-off ≤-1.8 still 
included 26% of individuals with normal bone status. The problem of how to 
use QUS results in the assessment of bone status was the subject of a review 
recently published by Nayak et al. (2006). The authors summarized data 
currently available in the literature, and using meta-analysis concluded that 
QUS results at the commonly used thresholds did not definitely exclude or 
confirm DXA established osteoporosis. 
Because of the high incidence of metabolic bone disease, IBD patients 
are at a high risk of bone fractures. However, the measurement of bone 
mineral density per se failed to prove as a reliable predictive parameter of 
fracture risk in this patient population (Stockbrugger 2002, Lee 2000). In our 
study group, 23% of patients reported a history of fragile fractures, and all 
QUS measurements were significantly lower in patients who had previously 
sustained at least one bone fracture. Similar findings are reported by Jahnsen 
et al. (1999) who observed significant between-group difference in SOS but 
not in BUA. In our study group, QUS and DXA differed in the ability to 
distinguish fracture from non-fracture patients with IBD. Thus, axial DXA was 
not significantly different between the fracture and non-fracture patients, 
whereas total hip DXA showed greater discriminatory potential. The objective 
   
 13 
of bone status assessment is to identify patients at risk of fracture, where 
QUS seems to provide some elements related to bone microarchitecture or 
elasticity rather than bone mineral content. For example, QUS technique has 
been shown to be a good predictor of fracture risk in postmenopausal women, 
independent of DXA (Knapp et al 2001); therefore, we consider this method 
being worthy of additional evaluation.  
A limitation of this study was the absence of long-term longitudinal QUS 
measurements, which would be necessary for comprehensive evaluation of 
the technique. This is supported by Zadik et al. (2005), who detected an early 
deterioration in bone quality by the follow-up of QUS measurements in a 
population of adolescents with active Crohn's disease. Comprehensive 
evaluation of the potential value of QUS technique in daily clinical practice 
requires additional clinical investigations in which medical treatment efficacy 
will be monitored by QUS parameters. To date, there are no study reports on 
using QUS as a criterion for therapy introduction.  
 In conclusion, our results suggest that calcaneal QUS measurements 
may identify patients with inflammatory bowel disease at a high risk of 
fracture, independently of DXA measurements. However, calcaneal QUS 
cannot successfully discriminate osteoporosis from osteopenia, which is 
necessary for the choice of an efficacious therapeutic option. The results of 
presented study suggest that data obtained by QUS cannot be considered a 
valuable alternative to DXA but may be used as a complementary option to 
classical densitometry due to QUS ability to predict fracture risk. Additional 
prospective studies in patients with inflammatory bowel disease are 
necessary to evaluate whether QUS can be used to monitor bone disease 
progression in parallel with therapeutic efficacy. 
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LIST of TABLE CAPTIONS 
 
 
Table 1 
Baseline Patient Characteristics 
Patients  
N (men/women) 126 (63/63) 
Age (yr.) 34.9±12 
Patients with inflammatory bowel disease                                            
Crohn's disease (n) 
Ulcerative colitis (n) 
94 
32 
Disease duration (years) (median; range) 6 (0.1-26) 
Body mass index (kg/m2) (mean, SD) 21.6±5 
Corticosteroid use > 3 months 
No 
Yes 
 
49 
77 
 
 
Table 2 
Calcaneal Quantitative Ultrasound Parameters in Patients with Inflammatory 
Bowel Disease and Reference Population 
 Patients Reference population p-level 
n 126 228  
Age (yr.)  34.9±12 32.5 ± 8 0.32 
BUA (dB/MHz) 66.7±16  88.7±13.8 0.00041 
BUA t-score -1.4±1.1   
SOS (m/s) 1529.7 ±31 1570±25 0.000001 
SOS t-score -1.7±1.2   
QUI- index 83.61±18 108.5±14.5 0.000001 
QUI t-score -1.69±1.2   
 
BUA= broadband ultrasound attenuation; SOS=speed of sound; QUI=stiffness 
index, and t-scores; all expressed as mean±SD 
Individual t-scores for BUA, SOS and QUI were calculated by mean (±SD) of 
reference population 
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LEGEND to FIGURES 
 
Figure 1. 
Correlation between calcaneal quantitative ultrasound parameters and 
disease duration in 126 patients with inflammatory bowel disease. A 
significant negative correlation was found with broadband ultrasound 
attenuation /BUA/ (r=-0.3 p=0.002), speed of sound /SOS/ (r=-0.35 p=0.001), 
and stiffness index /QUI/ (r=-0.33 p=0.001). 
 
Figure 2. 
T-scores of calcaneal quantitative ultrasound: BUA (broadband ultrasound 
attenuation), SOS (speed of sound) and QUI (stiffness index) in patients with 
inflammatory bowel disease with at least one fragile fracture (n=28) and with 
no fractures (n=98) in history. All three calcaneal t-scores were significantly 
lower in patients who had sustained fractures from non-fracture patients: BUA 
t-score p=0.008; SOS t-score p=0.02: QUI t-score p=0.001.  
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